Buy today 12/09/2020

 

BOXL 12/09/2020

 

TSLA 12/09/2020 red day

 

Inpixon 12/09/2020 and 27 march 2020 crash time market study

 

CRASH STUDY

ID	STOCK	DATE	TIME	your avg	market price	AMOUNT	TOTAL EQUITY	Field4	MARKET PRICE	CURRENT PRICE	AMT(NT)	NL	FILL PRICES	FILLED AMOUNT	FILLED TOTAL	Field2	TOTAL SHARE	Field3	AVG	REMARK NET LOSS
332	INPX	5/27/2021		$1.37	$1.03	501	$686.37		$1.03	($0.34)	501	($170.34)	$1.03	1000	$1,030.00	$1,716.37	1501	$1,716.37	$1.14

CRASH STUDY

ID	STOCK	DATE	TIME	your avg	market price	AMOUNT	TOTAL EQUITY	Field4	MARKET PRICE	CURRENT PRICE	AMT(NT)	NL	FILL PRICES	FILLED AMOUNT	FILLED TOTAL	Field2	TOTAL SHARE	Field3	AVG	REMARK NET LOSS
332	INPX	5/27/2021		$1.37	$1.03	501	$686.37		$1.03	($0.34)	501	($170.34)	$1.03	2000	$2,060.00	$2,746.37	2501	$2,746.37	$1.10

STOCK -FILL THE SHORT TABLE

ID	STOCK	REMARK PRICE	Field3	PRICES	AMOUNT	Field1	number	fill prices	fill dollar	total filled	total unit	average	NET LOSS	Field2	REMARK
302

 

ID	STOCK	REMARK PRICE	Field3	PRICES	AMOUNT	Field1	number	fill prices	fill dollar	total filled	total unit	average	NET LOSS	Field2	REMARK
302	INPX			$1.92	21	$40.32	100	$1.84	$184.00	$224.32	121	$1.85	0	(NEED TO FILL 100 SHARE AVG TO BE 1.85

Blood market day Dec 9 2020

 

LXRX down because of stimulus talk

 2:03p ET 7/22/2021 - Zacks

Will Lexicon Pharmaceuticals (LXRX) Report Negative Q2 Earnings? What You Should Know

Mentioned:

LXRX

Lexicon Pharmaceuticals (LXRX) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2021. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus Estimate

This drugmaker is expected to post quarterly loss of $0.16 per share in its upcoming report, which represents a year-over-year change of +75%.

Revenues are expected to be $0.03 million, down 99.7% from the year-ago quarter.

Estimate Revisions Trend

The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.

Price, Consensus and EPS Surprise

Earnings Whisper

Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Lexicon?

For Lexicon, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. This has resulted in an Earnings ESP of 0%.

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination makes it difficult to conclusively predict that Lexicon will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?

While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Lexicon would post a loss of $0.17 per share when it actually produced a loss of $0.15, delivering a surprise of +11.76%.

Over the last four quarters, the company has beaten consensus EPS estimates three times.

Bottom Line

An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Lexicon doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Lexicon Pharmaceuticals, Inc. (LXRX): Free Stock Analysis Report
 
To read this article on Zacks.com click here.